Xigad L 25 Tablet is a combination oral antidiabetic medication containing Empagliflozin 25 mg and Linagliptin 5 mg, indicated for the management of type 2 diabetes mellitus. Empagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, reduces renal glucose reabsorption, promoting urinary glucose excretion and thereby lowering blood glucose levels. Linagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, enhances incretin hormone activity, increasing insulin secretion and decreasing glucagon release in a glucose-dependent manner. The synergistic action of these agents provides effective glycemic control with a low risk of hypoglycemia. Xigad L 25 is recommended as an adjunct to diet and exercise to improve glycemic control in adults inadequately controlled on monotherapy or combination therapy. Clinical studies have demonstrated its efficacy in reducing HbA1c levels and improving fasting and postprandial glucose. It is generally well tolerated; however, potential adverse effects include urinary tract infections, genital mycotic infections, and nasopharyngitis. Caution is advised in patients with renal impairment, and it is contraindicated in type 1 diabetes and diabetic ketoacidosis. Regular monitoring of renal function and glycemic status is essential during treatment. Xigad L 25 offers a convenient once-daily dosing regimen, contributing to improved patient adherence in type 2 diabetes management.